Ghrelin: The Hunger Hormone
Ghrelin Biology
28 amino acids
Ghrelin is the only known circulating hormone that increases appetite. Discovered in 1999, it links the stomach to the brain's hunger, growth, and reward circuits.
Asakawa et al., Gut, 2001
Asakawa et al., Gut, 2001
View as imageBefore every meal, your stomach sends a signal to your brain: it is time to eat. That signal is ghrelin, a 28-amino-acid peptide produced by specialized X/A-like cells in the gastric fundus. Discovered by Masayasu Kojima and colleagues in 1999 during a search for the natural ligand of the growth hormone secretagogue receptor, ghrelin was the first hormone identified by "reverse pharmacology," finding the natural molecule that fits an already-known receptor.
Ghrelin occupies a unique position in endocrinology. It is the only known circulating hormone that stimulates appetite. While multiple hormones suppress hunger after meals (CCK, PYY, GLP-1, leptin), ghrelin is the sole peripheral orexigenic signal that tells the brain to seek food. Asakawa et al. (2001) characterized ghrelin as an appetite-stimulatory signal from the stomach with structural resemblance to motilin, a gut peptide that regulates gastric motility.[1] Wren et al. (2001) then demonstrated that ghrelin enhances appetite and increases food intake when administered to healthy human volunteers, the first proof that ghrelin drives hunger in people, not just rodents.[2]
This article maps ghrelin's biology: how it works, what it does beyond hunger, and why it matters for conditions ranging from obesity to cachexia to addiction. Each major section connects to a dedicated cluster article that explores the topic in depth.
Key Takeaways
- Ghrelin is the only known circulating appetite-stimulating hormone, rising before meals and falling after eating (Asakawa et al., 2001)
- Octanoylation (addition of an 8-carbon fatty acid to serine-3) by the enzyme GOAT is required for ghrelin to activate GHS-R1A and stimulate appetite
- Ghrelin simultaneously stimulates growth hormone release and appetite through the same receptor (GHS-R1A) but in different brain regions (Sun et al., 2004)
- Des-acyl ghrelin, the unacylated form comprising ~90% of circulating ghrelin, has independent biological activity including cardioprotective effects (Baldanzi et al., 2002)
- LEAP-2, a liver-derived peptide, functions as an endogenous ghrelin antagonist, rising after meals to counteract ghrelin's effects (Al-Massadi et al., 2018)
- Ghrelin receptor (GHS-R1A) mRNA is expressed in the hypothalamus, pituitary, heart, lung, liver, kidney, pancreas, and immune cells (Gnanapavan et al., 2002)
The Ghrelin Molecule: Structure and Activation
Ghrelin is synthesized as a 117-amino-acid preproghrelin precursor, which is cleaved to produce the mature 28-amino-acid peptide. What makes ghrelin biochemically unusual is a post-translational modification at serine-3: the addition of an octanoyl (8-carbon) fatty acid group by the enzyme ghrelin O-acyltransferase (GOAT). This octanoylation is essential for ghrelin to bind and activate its primary receptor, GHS-R1A. Without it, ghrelin cannot cross the blood-brain barrier efficiently and cannot stimulate appetite or growth hormone release through GHS-R1A.
The acylated form (acyl-ghrelin) represents only about 10% of total circulating ghrelin. The remaining ~90% is des-acyl ghrelin, also called unacylated ghrelin (UAG). For years, des-acyl ghrelin was considered biologically inert because it does not activate GHS-R1A. Gauna et al. (2007) challenged this view, demonstrating that unacylated ghrelin is not simply a non-functional form but acts as a full agonist at GHS-R1A at high concentrations and has independent receptor-mediated effects.[3] Baldanzi et al. (2002) showed that both acyl and des-acyl ghrelin protect cardiomyocytes and endothelial cells from apoptosis through ERK1/2 and PI3K/Akt signaling pathways, effects that are independent of GHS-R1A.[4] This established des-acyl ghrelin as a biologically active molecule with its own receptor system. The clinical implications are substantial: therapies that target acyl ghrelin (through GOAT inhibition, for example) would suppress appetite while preserving des-acyl ghrelin's cardiovascular and metabolic protective effects. Conversely, therapies that target GHS-R1A directly (receptor antagonists) would block both acyl and some des-acyl ghrelin effects, with potentially different safety and efficacy profiles.
The ratio of acyl to des-acyl ghrelin is dynamic and influenced by metabolic state. Fasting increases the proportion of acyl ghrelin (through increased GOAT activity), while feeding shifts the balance toward des-acyl ghrelin. This ratio may be a more sensitive marker of metabolic status than total ghrelin concentration, though measuring it accurately requires careful sample handling because acyl ghrelin is rapidly deacylated after blood collection. For more on ghrelin's heart effects, see our article on ghrelin's cardioprotective effects.
The Ghrelin Receptor: GHS-R1A Distribution
The growth hormone secretagogue receptor type 1A (GHS-R1A) was identified before ghrelin itself. Gnanapavan et al. (2002) mapped the tissue distribution of ghrelin and GHS-R1A mRNA in humans, finding receptor expression in the hypothalamus, pituitary, heart, lung, liver, kidney, pancreas, stomach, small and large intestine, adipose tissue, and lymphocytes.[5]
This wide distribution means ghrelin's biological effects extend far beyond appetite regulation. The hypothalamic expression mediates hunger. The pituitary expression mediates growth hormone release. The cardiac expression mediates cardioprotective effects. The pancreatic expression influences insulin secretion. The immune cell expression suggests roles in immune regulation that are only beginning to be characterized.
GHS-R1A has a distinctive pharmacological property: high constitutive activity. Unlike most G protein-coupled receptors, which are inactive until a ligand binds, GHS-R1A signals at approximately 50% of its maximum capacity even in the absence of ghrelin. This means the receptor is always "on" at a baseline level, and ghrelin binding increases signaling from this elevated baseline. The constitutive activity has implications for drug development: inverse agonists that suppress baseline activity could have different therapeutic profiles than neutral antagonists that simply block ghrelin binding. An inverse agonist would reduce reward circuit activity below the level maintained by constitutive GHS-R1A signaling, potentially causing anhedonia or reduced motivation. A neutral antagonist would only prevent ghrelin-induced increases above baseline, preserving the constitutive signaling that may serve homeostatic functions. This pharmacological distinction will influence both efficacy and side effect profiles for future ghrelin-targeting drugs.
Appetite Regulation: The Pre-Meal Signal
Ghrelin's most recognized function is appetite stimulation. Circulating ghrelin levels follow a meal-related pattern: they rise progressively during fasting, peak immediately before meals, and fall rapidly within 30-60 minutes of eating. This pattern earned ghrelin its designation as a "hunger hormone," though the term oversimplifies a system that also responds to stress, sleep, and metabolic status.
Shrestha et al. (2009) investigated the direct effects of nutrients on ghrelin release from the isolated stomach, finding that glucose, amino acids, and fatty acids all suppress ghrelin secretion, but through different mechanisms and with different dose-response relationships.[6] Protein and fat are more effective ghrelin suppressors than carbohydrates on a calorie-for-calorie basis, providing a metabolic rationale for the greater satiety associated with high-protein meals.
Hernandez et al. (2020) showed that moderate weight loss modifies the synthesis rhythms of both leptin and ghrelin without changing the subjective sensations of hunger and satiety.[7] This disconnect between hormonal signals and perceived hunger highlights that ghrelin is one input among many. The brain integrates ghrelin with signals from leptin, insulin, CCK, PYY, GLP-1, and learned associations to generate the conscious experience of appetite. Ghrelin alone does not determine whether you feel hungry; it biases the system toward hunger in a way that can be overridden by competing signals.
The clinical relevance of ghrelin's meal-related cycling extends to surgical interventions. Sleeve gastrectomy, which removes the gastric fundus where most ghrelin-producing cells reside, dramatically reduces circulating ghrelin levels. This reduction is thought to contribute to the appetite suppression and weight loss that follow the surgery, independent of the procedure's effects on gastric volume and nutrient transit. Roux-en-Y gastric bypass has more variable effects on ghrelin, depending on how much of the fundus is preserved and how nutrient delivery to the remaining stomach is altered.
Growth Hormone Release: The Original Function
Ghrelin was discovered because of its ability to stimulate growth hormone (GH) release from the pituitary. Sun et al. (2004) demonstrated that ghrelin stimulation of both GH release and appetite is mediated through GHS-R1A, but in different brain regions: the pituitary for GH release and the arcuate nucleus of the hypothalamus for appetite.[8] This means the same receptor-ligand pair produces two distinct physiological outputs depending on where in the brain the signaling occurs.
Bresciani et al. (2008) studied ghrelin's control of GH secretion and feeding behavior using GHS-R1A-specific approaches, confirming that the receptor mediates both effects but can be pharmacologically dissociated, at least partially.[9] This has implications for drug development: it may be possible to design GHS-R1A ligands that preferentially activate the GH-releasing pathway (useful for GH-deficient patients) without the appetite stimulation, or vice versa. For a dedicated exploration of this dual function, see our article on how ghrelin stimulates growth hormone and appetite simultaneously.
The Reward Connection: Ghrelin and Dopamine
Ghrelin's effects on the mesolimbic dopamine system transform it from a simple hunger signal into a motivational amplifier. Abizaid et al. (2006) demonstrated that ghrelin doubled VTA dopamine neuron firing rates and reorganized synaptic inputs, a finding that established ghrelin as a direct modulator of reward circuitry.[10]
Abizaid (2009) reviewed the ghrelin-dopamine connection, describing how ghrelin bridges metabolic state and motivated behavior: when energy stores are low and ghrelin is high, dopamine neurons become more responsive, making food (and other rewards) more motivationally salient.[11] This explains why food tastes better when you are hungry, why fasting increases drug-seeking behavior in animal models, and why ghrelin receptor antagonism reduces the rewarding properties of both food and drugs of abuse. For a deeper look at how hunger amplifies food reward, see our article on ghrelin and reward. For the addiction angle, see our article on ghrelin and alcohol craving.
Ghrelin in Metabolic Disease
Obesity: The Paradox of Low Ghrelin
Obese individuals have lower circulating ghrelin levels than lean individuals, a finding that initially seemed paradoxical: if ghrelin drives hunger, why is it low in people who overeat? The explanation lies in feedback regulation. Ghrelin is suppressed by insulin, and obese individuals typically have elevated insulin levels. The chronic hyperinsulinemia of obesity tonically suppresses ghrelin secretion, creating a state where baseline ghrelin is low but its functional significance may be altered.
Horvath (2003) reviewed ghrelin as a potential anti-obesity target, noting that despite low baseline levels in obesity, ghrelin receptor signaling may still drive feeding behavior through the receptor's constitutive activity and through altered sensitivity of target neurons.[12] Muccioli et al. (2002) described ghrelin's neuroendocrine and peripheral activities, documenting effects on energy metabolism, fat storage, and glucose homeostasis that extend beyond simple appetite stimulation.[13] For a detailed treatment of this topic, see our article on ghrelin resistance in obesity.
Insulin and Glucose
Ghrelin and insulin have a reciprocal relationship. Ghrelin inhibits insulin secretion from pancreatic beta cells, and insulin suppresses ghrelin release from the stomach. Heijboer et al. (2006) showed that ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice, improving hepatic insulin sensitivity while worsening peripheral sensitivity at the same dose.[14] This tissue-specific effect complicates any simple characterization of ghrelin as "insulin-opposing."
Peng et al. (2012) identified a specific mechanism for ghrelin's insulin-inhibiting effect: ghrelin regulates the expression of inwardly rectifying potassium channels in beta cells, hyperpolarizing the membrane and reducing insulin exocytosis.[15] This mechanism operates independently of ghrelin's appetite effects, occurring directly at the pancreatic beta cell rather than through central nervous system signaling. The practical consequence is that ghrelin may serve as a physiological brake on insulin secretion during fasting, preventing hypoglycemia by keeping insulin low when glucose availability is limited. During feeding, ghrelin suppression removes this brake, permitting the insulin surge needed to handle incoming nutrients. This coordinated system means ghrelin is not just an appetite hormone; it is a metabolic switch that simultaneously promotes energy seeking (through appetite and reward circuits) and prevents energy storage (through insulin suppression) during the fasting state.
The implication for type 2 diabetes is complex. Ghrelin receptor antagonists, being developed primarily for obesity and addiction, would remove the insulin-suppressing effect of ghrelin, potentially improving postprandial insulin secretion. But they would also remove ghrelin's role in preventing hypoglycemia during fasting, creating a potential safety concern for diabetic patients on insulin or sulfonylureas.
Cachexia: When Appetite Fails
In cancer, heart failure, and chronic kidney disease, appetite loss and muscle wasting (cachexia) are major contributors to morbidity and mortality. Ghrelin's appetite-stimulating properties make it a natural therapeutic candidate. Molfino et al. (2014) reviewed the trajectory from ghrelin's discovery to its potential application in cancer cachexia, noting that ghrelin administration increases food intake, body weight, and lean mass in cachectic animal models.[16] For a full analysis, see our article on ghrelin for cachexia.
LEAP-2: The Endogenous Ghrelin Brake
The ghrelin system includes a built-in counter-regulatory mechanism. LEAP-2 (liver-expressed antimicrobial peptide 2), originally identified as an antimicrobial peptide, was discovered to function as an endogenous GHS-R1A antagonist. Al-Massadi et al. (2018) described ghrelin and LEAP-2 as "rivals in energy metabolism," with LEAP-2 rising after meals (when ghrelin falls) and falling during fasting (when ghrelin rises).[17]
The ghrelin/LEAP-2 ratio may be a more physiologically relevant measure of ghrelin system activity than absolute ghrelin levels. A high ratio (high ghrelin, low LEAP-2) drives appetite and reward-seeking. A low ratio (low ghrelin, high LEAP-2) suppresses them. This ratio changes with metabolic state, feeding status, and liver function, providing an integrated readout of the body's energy balance.
The discovery of LEAP-2 also explains a long-standing puzzle: why ghrelin receptor antagonists do not consistently produce weight loss in obese animals. If endogenous LEAP-2 already partially suppresses ghrelin signaling in the fed state, adding a synthetic antagonist may provide limited additional benefit. The therapeutic opportunity may lie in augmenting LEAP-2 production rather than blocking ghrelin directly. Since LEAP-2 is produced by the liver, liver health directly influences LEAP-2 output, creating a connection between hepatic function and appetite regulation that may explain some of the appetite changes seen in liver disease.
The LEAP-2 discovery also reframes the ghrelin system as a push-pull mechanism rather than a simple on-off switch. The brain's appetite and reward circuits integrate the competing signals from ghrelin (push toward seeking) and LEAP-2 (pull toward satiety), with the balance determined by feeding status, liver function, and metabolic health. Disruption of either side of this balance, through excessive ghrelin signaling or insufficient LEAP-2 production, could contribute to pathological eating patterns.
What Remains Unknown
Despite over 25 years of research since ghrelin's discovery, several fundamental questions persist. The receptor for des-acyl ghrelin has not been definitively identified. Des-acyl ghrelin clearly has biological effects (cardioprotection, anti-proliferative activity, insulin sensitization) that do not require GHS-R1A, but the receptor mediating these effects remains elusive.
The regulation of GOAT activity is poorly understood. Since GOAT determines the ratio of acyl to des-acyl ghrelin, and this ratio may determine the net biological output of the ghrelin system, understanding what controls GOAT could be therapeutically important. GOAT inhibitors could suppress appetite without blocking des-acyl ghrelin's beneficial effects.
The interaction between ghrelin and the gut microbiome is emerging but not well characterized. Some bacterial species produce ghrelin-like molecules or influence ghrelin secretion through metabolite production. Whether this interaction is clinically meaningful remains to be determined, but it represents a potential link between the gut microbiome and appetite regulation beyond short-chain fatty acid production. Antibiotic-induced dysbiosis alters ghrelin levels in animal models, and probiotic supplementation modifies ghrelin dynamics in some human studies, though the effect sizes are small and inconsistent.
The sexual dimorphism in ghrelin biology is underappreciated. Women have higher circulating ghrelin levels than men, respond differently to ghrelin administration, and show different ghrelin dynamics during weight loss. Whether this translates to sex-specific therapeutic approaches has not been studied.
The role of ghrelin in intermittent fasting and time-restricted eating is of growing clinical interest. These dietary patterns involve extended fasting periods during which ghrelin levels would be elevated for longer than in conventional meal patterns. Whether the metabolic benefits attributed to intermittent fasting are partly mediated through ghrelin-dependent mechanisms (including growth hormone pulsatility and autophagy induction) or whether prolonged ghrelin elevation during fasting windows poses risks (through sustained reward circuit activation) is an open question with practical implications for millions of people following these dietary approaches.
The Bottom Line
Ghrelin is a 28-amino-acid stomach peptide that functions as the body's only known circulating appetite-stimulating hormone. Its biology extends far beyond hunger: ghrelin stimulates growth hormone release, amplifies dopamine-driven reward circuits, protects cardiomyocytes, and modulates insulin secretion. The acylated form (10% of circulating ghrelin) drives appetite through GHS-R1A, while des-acyl ghrelin (90%) has independent biological activity through an unidentified receptor. LEAP-2 serves as an endogenous ghrelin antagonist, and the ghrelin/LEAP-2 ratio may be more physiologically relevant than absolute ghrelin levels.